Wandercraft company profile
Wandercraft develops self-balancing robotic exoskeletons for rehabilitation and personal mobility. Its Atalante X system supports gait therapy in clinical settings, while Eve is aimed at upright walking and daily mobility for people with severe mobility disabilities.
Facts
- Segment: Healthcare
- Country: France
- Founded: 2012
- Website: https://www.wandercraft.eu
Profile sections
- Summary
- Market context
- Products
- Facts
- Funding
- Investors
- Context / Market Position
- Events
- Team
- Supply chain relationships
- Relationships
- Context tags
- Record / Articles
- Sources
Summary
Wandercraft develops self-balancing robotic exoskeletons for rehabilitation and personal mobility. Its Atalante X system supports gait therapy in clinical settings, while Eve is aimed at upright walking and daily mobility for people with severe mobility disabilities.
Market context
One of the few companies achieving real-world deployment of dynamic bipedal robotics in clinical environments, with systems already in use across rehabilitation centers. Wandercraft develops robotic exoskeletons for mobility assistance and rehabilitation.
- Capability: Powered exoskeleton locomotion for human users Balance and gait control systems Assistive mobility in clinical and real-world environments
- Strategic position: Positioned within medical and assistive robotics Focused on restoring mobility through robotic systems
Facts
- Website: https://www.wandercraft.eu
- HQ: Paris, France
- Founded: 2012
- Segment: Healthcare
- Funding total: $120M
- Known funding rounds: 2
- Latest funding date: 2025-06-11
Funding
- 2025-06-11 - Series D - $74M - Wandercraft secures €64.3 million in Series D funding - source: eu-startups.com
- 2023-12-28 - Loan - $29M - Wandercraft secures €25M EIB financing for exoskeleton development - source: eib.org
Investors
- European Investment Bank - Lead - Government / Public - 2 funding events - repeat backer - first seen 2023-12-28 - latest 2025-06-11
- AG2R LA MONDIALE - Participant - Unknown - 1 funding event - first seen 2025-06-11
- Bpifrance PSIM - Lead - Angel / Individual - 1 funding event - first seen 2025-06-11
- Cemag Invest - Participant - Angel / Individual - 1 funding event - first seen 2025-06-11
- LBO France - Participant - Angel / Individual - 1 funding event - first seen 2025-06-11
- Martagon Capital - Participant - Vc - 1 funding event - first seen 2025-06-11
- Mutuelles Impact - Participant - Angel / Individual - 1 funding event - first seen 2025-06-11
- Quadrant Management - Lead - Angel / Individual - 1 funding event - first seen 2025-06-11
- Renault Group - Lead - Angel / Individual - 1 funding event - first seen 2025-06-11
- Teampact Ventures - Lead - Vc - 1 funding event - first seen 2025-06-11
- XAnge - Participant - Unknown - 1 funding event - first seen 2025-06-11
Self-balancing robotic exoskeletons for rehabilitation and personal mobility
Wandercraft develops self-balancing robotic exoskeletons for rehabilitation and mobility assistance. Its Atalante platform has commercial and clinical use, while newer personal mobility work points toward home and community use for people with mobility impairments.
- Target environment: Rehabilitation clinics, hospitals, mobility-assistance settings, personal exoskeleton trials and healthcare robotics environments.
- Deployment model: Healthcare robotics model built around exoskeleton hardware, clinical validation, regulatory clearance, partnerships and expansion toward personal mobility devices.
- Customer context: Rehabilitation hospitals, clinicians, patients, healthcare systems, payers and partners building mobility-assistance infrastructure.
- Workflow context: Gait rehabilitation, self-balancing walking, mobility assistance, clinical therapy, exoskeleton control, patient training and personal mobility support.
- Commercial maturity: Wandercraft has one of the more mature walking exoskeleton programs, with commercial rehabilitation use and continued personal mobility development. Personal-use scale remains dependent on regulatio…
- Market position: French healthcare robotics company positioned around dynamic self-balancing exoskeletons.
- Adoption constraints: Regulatory clearance, reimbursement, clinical adoption, safety, cost, training requirements, home-use reliability and manufacturing scale.
- Adjacent context: Healthcare robotics, exoskeletons, rehabilitation robots, mobility assistance, bipedal locomotion and assistive robotics.
- Source confidence: high
Events
- 2026-03-12 - Deployment - Renault Group deploys 350 Wandercraft Calvin-40 humanoid robots - • Renault Group deployed 350 Wandercraft Calvin-40 humanoid robots in its factories over an 18-month period.
- 2025-08-01 - Research Publication - Atalante X Powered Exoskeleton - The publication is an exact Atalante X powered-exoskeleton research record.
- 2025-06-11 - Funding - Wandercraft secures €64.3 million in Series D funding - • Wandercraft secured €64.3 million in a Series D funding round on June 11, 2025.
- 2024-02-13 - Regulatory - Wandercraft's Atalante X exoskeleton receives FDA clearance for spinal cord injury rehabilitation - • Wandercraft received FDA clearance for its Atalante X exoskeleton to be used in rehabilitat…
- 2024-02-13 - Regulatory - Wandercraft's Atalante X receives second FDA clearance - • Wandercraft received FDA clearance for Atalante X for rehabilitation in individuals with spinal cord injuries at levels T5 to L5.
- 2023-12-28 - Funding - Wandercraft secures €25M EIB financing for exoskeleton development - • Wandercraft received €25 million in financing from the European Investment Bank (EIB) on December 28, 2023.
Team
- Matthieu Masselin - Co-founder - Co-founder connected to Wandercraft's self-balancing exoskeleton and rehabilitation robotics development.
- Alexandre Boulanger - Co-founder - Co-founder associated with Wandercraft's robotic exoskeleton development and self-balancing mobility technology.
Supply chain relationships
- Renault Group - deployment_partner - Wandercraft deployed its Calvin humanoid exoskeleton at Renault Group manufacturing facilities for worker assistance.
Relationships
- Renault Group - customer - Renault Group deploys 350 Wandercraft Calvin-40 humanoid robots
Context tags
- Rehabilitation robotics - Peer Group
- Medical exoskeletons - Peer Group
- Gait rehabilitation - Workflow
- Exoskeleton gait training - Workflow
- Self-balancing mobility control - Capability
- Rehab exoskeleton OEM - Stack Layer
- Rehabilitation robotics platform - Stack Layer
- Rehab exoskeleton builder - Peer Group
- Self-balancing rehab exoskeleton builder - Peer Group
- Powered limb assistance - Capability
- Home assistive care - Customer Environment
- Rehabilitation clinics - Customer Environment
Record / Articles
- 2026-03-12 - Renault prepares Calvin humanoids for factory work with Wandercraft - Renault plans to deploy hundreds of Calvin humanoids developed with Wandercraft across its manufacturing operations, extending the Frenc…
- 2025-06-11 - Wandercraft is carrying exoskeleton proof into humanoid factory work - Wandercraft raised $75 million in Series D funding in June 2025 to scale Atalante X, prepare Eve, and develop Calvin-40 with Renault as…
Wandercraft canonical Korthos profile